Glucocorticoids
ATC code: H02AB02 (Dexamethasone)
Binds intracellular glucocorticoid receptors, translocates to the nucleus, and suppresses transcription of pro-inflammatory genes. Potent anti-inflammatory activity – 25–30 times stronger than hydrocortisone. Virtually no mineralocorticoid activity. Long-acting – half-life 36–54 hours.
First line
First-line for peritumoral cerebral edema and perioperative management in neurosurgery. Loading dose 10 mg IV, then 4 mg every 6 hours. Reduces vascular permeability and vasogenic edema. Not effective for cytotoxic edema – for example, in ischemic stroke.
Adjunct
Component of standard triple antiemetic regimen for chemotherapy. Per ASCO and NCCN guidelines, dexamethasone is given with a 5-HT3 receptor antagonist and an NK1 receptor antagonist. Doses 8–20 mg depending on the emetogenicity of the regimen.
First line
First-line in hospitalized COVID-19 patients requiring supplemental oxygen or mechanical ventilation. The RECOVERY trial (2020, over 6,000 patients) showed a one-third reduction in 28-day mortality in ventilated patients and a one-fifth reduction in those on oxygen. No benefit in patients not requiring oxygen. Dose: 6 mg/day for 10 days.
The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.
Not recommended
Dexamethasone is a potent systemic corticosteroid. It is prescribed for acute autoimmune crises, severe allergic reactions, cerebral edema, chemotherapy, and as part of protocols for severe infections (bacterial meningitis, severe oxygen-requiring COVID-19 per RECOVERY 2021). For chronic fatigue without a confirmed diagnosis, dexamethasone is not indicated. The drug has a catastrophic risk profile on long-term use: HPA axis suppression (dangerous withdrawal syndrome), steroid diabetes, osteoporosis with fractures, avascular necrosis of bones, immunosuppression with risk of severe infections, psychiatric disturbances (psychosis, insomnia), cataract, and hypertension. If dexamethasone was prescribed for chronic fatigue without a confirmed diagnosis, seek a second opinion immediately.
11 pairs found. Sorted from critical to minor.
Mechanism
Dexamethasone is a CYP3A4 and P-glycoprotein inducer. It reduces apixaban (a substrate of both) levels by 30–50%, raising thrombotic event risk.
Symptoms
The patient feels no symptoms. Stroke risk in atrial fibrillation rises, as do deep vein thrombosis and pulmonary embolism risks.
Management
For prolonged systemic dexamethasone, do not increase apixaban (no titration data); switch to warfarin with INR monitoring instead. For short dexamethasone pulse therapy (1–3 days), no clinically significant effect.
Sources
Mechanism
Dexamethasone is a potent CYP3A4 inducer and weak CYP2B6 inducer (which metabolises bupropion). Bupropion levels may fall, giving partial loss of antidepressant effect. The glucocorticoid itself also lowers the seizure threshold.
Symptoms
Seizures (generalised tonic-clonic or focal), agitation, tremor, insomnia. Patients with prior epilepsy or eating disorders are at particular risk.
Management
For prolonged dexamethasone therapy, bupropion may be increased by 50% with clinical monitoring. For short courses, no adjustment is usually needed. After dexamethasone stops, induction persists for 1–2 weeks.
Mechanism
Additive tendon injury risk. Fluoroquinolones disrupt collagen synthesis in tendon fibres; glucocorticoids suppress repair and weaken the collagen matrix. carries a boxed warning for tendinitis and Achilles tendon rupture.
Symptoms
Pain and swelling in the Achilles tendon (less often other large tendons: biceps, rotator cuff). Sudden 'snap' and inability to bear weight indicates rupture. Symptoms typically appear within 1–4 weeks and may persist for months after withdrawal.
Management
Avoid the combination, especially in patients over 60, post-kidney-transplant, and with athletic activity. Alternative antibiotics: a cephalosporin or nitrofurantoin (no tendon effect). If ciprofloxacin is needed, limit physical activity for the entire course and 1 month after.
Mechanism
Additive ulcerogenic effect. Dexamethasone suppresses GI mucosal repair; aspirin blocks protective prostaglandins.
Symptoms
Epigastric pain, nausea, heartburn. With prolonged therapy: peptic ulcer and GI bleeding risk (black stools, vomiting blood or coffee-ground material). Older patients and prior peptic ulcer disease: higher risk.
Management
For short dexamethasone courses, cardioprotective aspirin is acceptable with pantoprazole cover. For prolonged systemic glucocorticoid therapy, watch dyspepsia symptoms; consider stool occult blood testing as needed.
Mechanism
Dexamethasone is a weak CYP3A4 inducer and may slightly reduce amiodarone levels in long-term therapy. The additive QT effect is minimal but persists in predisposed patients.
Symptoms
Short dexamethasone pulses usually cause no symptoms. QT prolongation on ECG. Dizziness, syncope, palpitations. Rarely: polymorphic ventricular tachycardia (torsades de pointes). Risk is higher with hypokalaemia, hypomagnesaemia, bradycardia, and ischaemic heart disease.
Management
For short dexamethasone courses (3–7 days), no specific adjustment needed. For long-term therapy, check ECG every 3 months. In atrial fibrillation with uncontrolled rate, consider raising amiodarone by 50–100 mg/day.
Mechanism
Dexamethasone is a weak CYP3A4 inducer. With prolonged therapy, amlodipine plasma levels may modestly fall and the antihypertensive effect weaken.
Symptoms
Gradual blood pressure rise 2–4 weeks after starting the glucocorticoid. In heart failure: oedema, weight gain.
Management
For short dexamethasone courses (up to 7 days), no adjustment. For prolonged systemic therapy, monitor blood pressure every 2 weeks; increase amlodipine if needed.
Mechanism
Dexamethasone induces CYP3A4. With prolonged therapy, atorvastatin plasma levels may fall modestly and lipid-lowering effect weakens.
Symptoms
The patient feels nothing. Laboratory: cholesterol and total cholesterol rise during prolonged systemic glucocorticoid therapy.
Management
For short dexamethasone courses, no adjustment. For prolonged systemic therapy, monitor lipid profile every 2–3 months; increase atorvastatin by 25–50% if needed.
Mechanism
Dexamethasone causes sodium and water retention via mineralocorticoid effect, reducing the antihypertensive effect of the beta-blocker.
Symptoms
Gradual blood pressure rise 2–4 weeks after starting the glucocorticoid. In heart failure: oedema, weight gain.
Management
For short dexamethasone courses (up to 7 days), no adjustment. For prolonged systemic therapy, increase bisoprolol or add a diuretic (hydrochlorothiazide, indapamide) with blood pressure monitoring.
Mechanism
Dexamethasone has minimal mineralocorticoid activity but, at high doses and prolonged use, blunts the ACE inhibitor's antihypertensive effect. The effect is weaker than with prednisolone.
Symptoms
Possible rise in blood pressure with long-term therapy. Weakness, fatigue, paraesthesias, arrhythmia. Symptoms develop at potassium above 5.5 mmol/L; life-threatening above 6.5 mmol/L.
Management
For short dexamethasone courses, no specific adjustment needed. For long-term therapy, check BP every 1–2 weeks. If BP rises, intensify antihypertensive therapy (increase enalapril or add a thiazide). Potassium and creatinine monthly.
Mechanism
Dexamethasone stimulates gluconeogenesis and reduces tissue insulin sensitivity. The glycaemic effect is stronger than with prednisolone due to long half-life and high potency.
Symptoms
Return of thirst and polyuria, rising fasting glucose, fatigue. In type 2 diabetes, possible decompensation with rise of 0.5–1.5%.
Management
For short dexamethasone pulses (1–3 days, e.g. cerebral oedema or post-chemotherapy), no metformin adjustment needed — transient hyperglycaemia is tolerated. For long-term therapy, increase metformin or add long-acting insulin. Check glucose twice daily in the first week.
Mechanism
Dexamethasone is a weak CYP3A4 inducer and a potential weak CYP2C9 inhibitor. Effect on INR is unpredictable and usually mild: INR may fall in some patients and rise in others.
Symptoms
Gum bleeding, epistaxis, bruising without trauma, black or tarry stools, haematuria. Higher risk in older patients, prior peptic ulcer disease, and chronic kidney disease.
Management
For short dexamethasone courses (3–5 days), no special monitoring needed. For longer therapy, check INR at one week, then every 2 weeks. Beyond the INR effect, glucocorticoids add gastrointestinal bleeding risk via mucosal ulcerogenic action.
Opens the checker prefilled with this drug. Pick the second one from your regimen.
Direct links to regulator labels. Open in a new tab.
FDA category C. Crosses the placenta (unlike prednisolone, which is metabolized by the placenta). High doses in the first trimester are associated with a small increased risk of cleft palate. Used for strict indications – for example, fetal lung maturation in threatened preterm labor.
Compatible for short courses. Hale L3 (systemic), L2 (topical and inhaled). Transfers into milk in small amounts; single doses and short courses (for example, 12 mg for fetal lung maturation or to suppress oedema) do not produce clinically meaningful infant exposure. With prolonged high-dose systemic therapy (over 20 mg per day), monitor infant growth, weight gain and adrenal function. Half-life ~36 hours; no feeding pauses needed.
Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.
Dexamethasone is evaluated for the following indications with varying evidence strength: Chemotherapy-induced nausea and vomiting prophylaxis (evidence tier A), Cerebral edema (evidence tier A), COVID-19 (evidence tier A). See the full indication matrix with dosing and citations above on this page.
Common side effects of Dexamethasone (≥ 1 in 100): Hyperglycemia, Increased appetite, Insomnia, Mood changes – irritability, euphoria, Dyspepsia. See the Safety section for uncommon and serious reactions.
FDA category C. FDA category C. Crosses the placenta (unlike prednisolone, which is metabolized by the placenta). High doses in the first trimester are associated with a small increased risk of cleft palate. Used for strict indications – for example, fetal lung maturation in threatened preterm labor.
Compatible for short courses. Hale L3 (systemic), L2 (topical and inhaled). Transfers into milk in small amounts; single doses and short courses (for example, 12 mg for fetal lung maturation or to suppress oedema) do not produce clinically meaningful infant exposure. With prolonged high-dose systemic therapy (over 20 mg per day), monitor infant growth, weight gain and adrenal function. Half-life ~36 hours; no feeding pauses needed.
Dexamethasone is contraindicated in: Systemic fungal infections (unless patient is on antifungal therapy); Hypersensitivity to dexamethasone; Live vaccines at immunosuppressive doses. Full list in the Safety section.